Growth Metrics

Beta Bionics (BBNX) Return on Capital Employed (2025 - 2026)

Beta Bionics recorded quarterly Return on Capital Employed of 26.35% in Q1 2026, down 9.72% quarter-over-quarter from 24.02% in Q4 2025, and down 240.0% year-over-year from 18.82% in Q1 2025.

Beta Bionics' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 26.35% for Q1 2026.

  • In Q1 2026, Return on Capital Employed fell 240.0% year-over-year to 26.35%; the TTM figure through Mar 2026 stood at 26.35% (down 240.0% YoY), while the FY2025 annual figure was 34.42%, up 721.0% from the prior year.
  • Return on Capital Employed came in at 26.35% for Q1 2026 at Beta Bionics, down from 24.02% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 19.88% in Q2 2025 to a low of 26.35% in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 9.61%
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 12.24%
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 7.36%
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 9.62%
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 11.13%
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 7.62%
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 24.24%
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 9.30%
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 11.57%
10 Beta Bionics 572.34 Mn 542.03 Mn 16.44 Mn -26.35%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -26.35%
Dec 31, 2025 -24.02%
Sep 30, 2025 -22.52%
Jun 30, 2025 -19.88%
Mar 31, 2025 -23.95%